Category HNE LHD
SITUATION Due to a global shortage, many Hunter New England Local Health District sites have low supplies of piperacillin+tazobactam with shortages likely until after September. It is essential that further use of this agent is conserved as below. Amoxycillin+clavulanate is now available in a parenteral form and is a suitable option in many circumstances, contingent on local […]
Cumulative antibiograms provide a summary of current bacterial antimicrobial susceptibility for key pathogens in urine and non-urine specimens. Treatment recommendations based on Therapeutic Guidelines, Antibiotic, Edition 15, 2014 are included in each report. These are prepared by Pathology North, Microbiology for Hunter, New England and Lower Mid-north coast regions. The antibiogram reports include analyses of […]
The Special Access Scheme (SAS) allows practitioners to import/gain access to therapeutic goods currently not registered on the Australian Register of Therapeutic Goods (ARTG) for a single patient on a case by case basis. Fosfomycin (one such SAS drug) is a broad spectrum antibiotic belonging to the phosphonic acid derivative drug class (other examples in this drug class include foscarnet and adefovir).
Useful information sheet on alternatives from NCAS. N.B. oral bioavailability of metronidazole is high. Previously published ANZ anaerobe susceptibility data will be re-published on AIMED soon.
The Hunter New England Local Health District (HNELHD) Quality Use of Medicines mobile-enabled website has recently been updated to include the latest version of some commonly used antibiotic and other guidelines (National and Local). Guidelines available include Surgical Antibiotic Prophylaxis, Community and Hospital Acquired Pneumonia, First-Dose Sepsis, Warfarin prescribing, Heparin Infusion and Potassium Replacement. The […]
Fluoroquinolones (ciprofloxacin, norfloxacin and moxifloxacin) have serious potential side effects, and are best used only for directed therapy of serious multi-resistant Gram negative infections where no other safer alternatives are available. 14 of our 32 hospital facilities in HNELHD overuse these agents with 2016 average FQ usage above our current benchmark of 30 defined daily doses per 1000 patient-days. […]
Hot of the press – our updated antibiograms with commentaries – revised format. Some take home messages from these analyses: Gentamicin retains excellent coverage of aerobic Gram negative bacteria and remains the best choice for empirical Gram negative cover, as reflected in the Australian Therapeutic Guidelines: Antibiotic recommendations. The proportion of non-urinary isolates of Staph. aureus […]
Here are our local Pathology North (NSW) comments together with their rationale: Positive CDI test result comment (no test of clearance required!): The duration of contact precautions following recovery are controversial. Patients will continue to excrete C. difficile for weeks following recovery and can represent a cross infection risk. However continent patients with formed stool who […]
A call from a local GP last week – 53 year old woman who was given a course of oral amoxycillin+clavulanate for respiratory infection and then developed moderately severe enteritis associated with CT evidence of colitis. Stool testing for C. difficile toxin genes was positive, confirming a diagnosis of CDI. She responded to a 10 day course […]
Please consult HealthPathways for up-to-date advice on patient management and referral pathways for active treatment. If logon details for HP required, please contact aimed site administrator – firstname.lastname@example.org. Dr Josh Davis from Newcastle also provided these updates on viral hepatitis with clear messages for general practice – a good starting point. Excerpt from Hepatitis C pathway: General practitioners […]